FibroTest-ActiTest as a non-invasive marker of liver fibrosis (Q28299279)

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biomarkers of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Progression of liver fibrosis among injection drug users with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

A novel panel of blood markers to assess the degree of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Diagnostic value of FibroTest with normal serum aminotransferases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021

Guidelines for the diagnosis of uncomplicated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2808%2973991-5

7 January 2021